The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Elranatamab for R/R myeloma: long-term updates from MagnetisMM-3 & real-world safety of this agent
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses updated overall survival (OS) data from the MagnetisMM-3 trial (NCT04649359) evaluating elranatamab in relapsed/refractory (R/R) multiple myeloma. Prof. Mohty also shares insights into the efficacy of this agent in the real-world setting, based on findings from a French compassionate use program. Elranatamab has demonstrated encouraging safety and efficacy in a difficult-to-treat population. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: Jazz Pharmaceuticals, Sanofi, Janssen; Honoraria: Gilead, GSK, Pfizer, Adaptive Biotechnologies, Oncopeptides, Astellas, Novartis, Takeda, Amgen, Jazz Pharmaceuticals, Celgene, Bristol Myers Squibb, Sanofi, Janssen.
